

# **INFLIXIMAB**

(Remicade or Biosimilars)

## **Outpatient Infusion**

# **Order Form**

Patient Name			
DOB			
Address			
Phone			
Order Status   □ New Order   □ Renewal		☐ Dose or Frequency Change	
Allergies:			Weight: Height:
Diagnosis	<ul><li>☐ Psoriatic arthritis</li><li>☐ Ulcerative Colitis</li><li>☐ Pt</li></ul>	nkylosing spondylitis aque Psoriasis Istular Psoriasis Iher:	Diagnosis Code:
Required Information	Negative Quantiferon TB, T-spot or chest x-ray (no active disease)		Date:
	Diagnostic Hepatitis B panel		Date:
	CBC and CMP		Date:
Please include labs attached and refer to page 2 for Required Documentation			
Labs	☐ Hepatic Function panel every 3 mon	ths	☐ Other:
□ Diphenhydramine ○ PO ○ 25 mg □ Acetaminophen ○ 325 mg ○ 650 mg □ Other:    Other:   Medication Order □ Induction: Week 0, 2, 6, then every □ Induction: □ Induction: Week 0, 2, 6, then every □ Induction: Week 0, 2, 6, th			
<ul> <li>□ Inflectra (infliximab-dyyb)</li> <li>□ Renflexis (infliximab-abda)</li> <li>□ Avsola (infliximab-axxq)</li> <li>□ Other:</li> <li>□ Dose will be rounded up to</li> </ul>			weeks thereafter Maintenance: Every weeks Other:
Remicade has several biosimilars. Certain payors may require use of a specific biosimilar. Please select allowed alternative if Remicade is not covered by payor. If more than one, note preference.    Alternative(s):			
Infusion Reaction Medications  Hypersensitivity Reaction Protocol will be utilized unless otherwise specified			
Provider (print name):		Date:	
Provider Signature:		NPI:	
Office Phone:		Office Fax:	



### **INFLIXIMAB**

(Remicade or Biosimilars)

### **Order Form**

#### **Required Documentation**

- H&P or progress note supporting diagnosis.
- Documented negative TB within 6 months of initiation.
- Chron's: Inadequate response to systemic corticosteroids
- UC: Inadequate response to systemic corticosteroids
- RA: documentation of methotrexate combination or intolerance or contraindication. Positive RF or anti-CCP
- AS: Inadequate response to two or more NSAIDs or intolerance or contraindication to two or more NSADs
- PsA: Inadequate response to another conventional synthetic drug or intolerance or enthesitis or predominately axial disease or severe disease
- PsO: Inadequate response or intolerance to UVB, PUVA or pharmacologic treatment with methotrexate, cyclosporin, acitretin or clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine and acitretin.
- Medication history
- Recent labs (as above) and/or diagnostic test results

#### **Outpatient Infusion**